Drug intelligence / Profile preview

P-1

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes

Overview

P-1 is a component, likely a specific variant of proso millet protein (PMP), utilized in the fabrication of complex nanoparticles (e.g., Cur-EGCG-NaCas-P-1 (2) complex nanoparticles). These nanoparticles are designed as a delivery system for hydrophobic bioactive compounds, such as curcumin, enhancing their physical stability, encapsulation efficiency, and antioxidant activity. The formulation involves electrostatic interactions, hydrophobic interactions, and hydrogen bonding. These nanoparticles show potential for applications in functional foods and pharmaceutical formulations.

Beyond the preview

Go deeper on P-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-1.

Explore the full profile